Integral Diagnostics: FY26 results and new CFO appointment

Integral Diagnostics delivered double-digit profit growth and appointed a new CFO.

The Integral Diagnostics Ltd (ASX: IDX) share price is in focus today after reporting preliminary FY26 results, with revenue climbing around 25% and operating NPAT surging by approximately 50%.

Two CEOs shaking hands on a deal.

Image source: Getty Images

What did Integral Diagnostics report?

  • Revenue expected at $788–$790 million, up ~25% from FY25 ($628.0m)
  • Operating EBITDA forecast at $164–$165 million, up ~30% from FY25 ($126.5m)
  • Operating EBITDA margin of ~20.8%–21.0%, 80 basis points higher vs last year
  • Operating NPAT projected at $47–$48 million, up ~50% from FY25 ($31.6m)
  • Diluted operating EPS estimated at 12.5c–12.7c, up ~23% from FY25 (10.2c)
  • Net Debt to Operating EBITDA improved to 2.3x from 2.6x

What else do investors need to know?

Integral Diagnostics' preliminary numbers include a full twelve-month contribution from the Capitol Health acquisition, which previously had only a partial year impact. Capital expenditure was $50 million, falling within the company's guidance range.

In leadership news, Integral Diagnostics has appointed Ms Jenny Martin as its new Chief Financial Officer. She brings over 25 years' experience in finance and healthcare technology, taking over from outgoing CFO Craig White, who will retire following an orderly transition period.

What's next for Integral Diagnostics?

Shareholders can expect audited FY26 results as scheduled on 25 August 2026, with a results roadshow planned featuring both the new and outgoing CFO. The leadership transition, coupled with improved balance sheet discipline and continued investment, positions IDX for its next stage of growth across Australia and New Zealand.

Integral Diagnostics' outlook includes a focus on operational discipline, integrating recent acquisitions, and enhancing its unique medical leadership model to support future expansion.

Integral Diagnostics share price snapshot

Over the past 12 months, Integral Diagnostics shares have declined 20%, trailing the All Ordinaries Index (ASX: XAO), which has risen 5% over the same period.

View Original Announcement

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

More on Healthcare Shares

Doctor with stethoscope typing on her computer.
Healthcare Shares

$128 million contract win: Are Pro Medicus shares a strong buy?

I remain a fan of this healthcare technology company, and today's announcement gives me another reason to be optimistic.

Read more »

A woman looks nonplussed as she holds up a handful of Australian $50 notes.
Healthcare Shares

At $199, are CSL shares a bargain buy or a risky investment?

Here's my verdict on the ASX biotech stock.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

Falling pills in a blue background.
Healthcare Shares

Mayne shares are up 80% on takeover news, but there's still money to be made

Major shareholders are backing the deal in.

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »